1.Macrogol versus Vaseline in the Treatment of Superficial Sacral Pressure Ulcers: A Retrospective, Comparative Study
Kuniaki KURIBAYASHI ; Hiroe TAKEUCHI ; Yoshikazu ENDO ; Shingo TOMITA ; Yasushi NISHIKOURI
An Official Journal of the Japan Primary Care Association 2018;41(2):60-64
Introduction: Recently, ointment bases have been considered to play more important roles in wound healing than those played by their main agents. There has been an increasing interest in the use of macrogol (MAC) because it is considered to accelerate the epithelialization of pressure ulcers. We compared the effectiveness of MAC and vaseline (VAS) in healing d2 (partial-thickness skin loss) sacral pressure ulcers.Methods: Twenty-five cases of d2 sacral pressure ulcers, which occurred in patients in long-term-care beds in our hospital, were initially included in this study. VAS was applied to d2 sacral pressure ulcers in 13 cases (VAS group), and MAC was also applied in 12 cases (MAC group). After VAS or MAC was applied, all pressure ulcers were covered with non-adhesive, water-absorbing gauzes. One case of in-hospital mortality was excluded from the MAC group; therefore, 13 cases in the VAS group and 11 cases in the MAC group were included in the final analysis. The healing periods were compared between the two groups.Results: There were no significant differences in the patients' background between the two groups. The healing period (days) in the MAC group (8 [7-11.5]) was significantly shorter than that in the VAS group (16 [12-32]) (P=0.029).Conclusion: MAC may accelerates the healing process of d2 sacral pressure ulcers.
2.Depression Promotes the Onset of Irritable Bowel Syndrome through Unique Dysbiosis in Rats
Takeshi TAKAJO ; Kengo TOMITA ; Hanae TSUCHIHASHI ; Shingo ENOMOTO ; Masaaki TANICHI ; Hiroyuki TODA ; Yoshikiyo OKADA ; Hirotaka FURUHASHI ; Nao SUGIHARA ; Akinori WADA ; Kazuki HORIUCHI ; Kenichi INABA ; Yoshinori HANAWA ; Naoki SHIBUYA ; Kazuhiko SHIRAKABE ; Masaaki HIGASHIYAMA ; Chie KURIHARA ; Chikako WATANABE ; Shunsuke KOMOTO ; Shigeaki NAGAO ; Katsunori KIMURA ; Soichiro MIURA ; Kunio SHIMIZU ; Ryota HOKARI
Gut and Liver 2019;13(3):325-332
BACKGROUND/AIMS: Although studies using conventional animal models have shown that specific stressors cause irritable bowel syndrome (IBS), it is unclear whether depression itself causes IBS. Our aim was to establish a rat model to determine if depression itself promotes the onset of IBS and to elucidate the role of gut microbiota in brain-gut axis pathogenesis during coincident depression and IBS. METHODS: Rat models of depression were induced using our shuttle box method of learned helplessness. Visceral hypersensitivity was evaluated by colorectal distension (CRD) to diagnose IBS. Gut microbiota compositions were analyzed using high-throughput sequencing. In the subanalysis of rats without depression-like symptoms, rats with posttraumatic stress disorder (PTSD) were also examined. RESULTS: The threshold value of CRD in depressed rats was significantly lower than that in control rats. Microbial community analysis of cecal microbiota showed that the relative abundance of Clostridiales incertae sedis, the most prevalent microbe, was significantly lower in depressed rats than in control rats. The distribution pattern of the microbiota clearly differed between depressed rats and control rats. Neither visceral hypersensitivity nor the composition of gut microbiota was altered in rats with PTSD-like phenotypes. CONCLUSIONS: Our rat model of depression is useful for clarifying the effect of depression on IBS and suggests that depression itself, rather than specific stressors, promotes the onset of IBS. Further, we provided evidence that various psychiatric diseases, viz., depression and PTSD, are associated with unique gut microbiota profiles, which could differentially affect the onset and progression of coincident IBS.
Animals
;
Clostridiales
;
Depression
;
Dysbiosis
;
Gastrointestinal Microbiome
;
Helplessness, Learned
;
Hypersensitivity
;
Irritable Bowel Syndrome
;
Methods
;
Microbiota
;
Models, Animal
;
Phenotype
;
Rats
;
Stress Disorders, Post-Traumatic
3.Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study
Michihiro IWAKI ; Hideki FUJII ; Hideki HAYASHI ; Hidenori TOYODA ; Satoshi OEDA ; Hideyuki HYOGO ; Miwa KAWANAKA ; Asahiro MORISHITA ; Kensuke MUNEKAGE ; Kazuhito KAWATA ; Tsubasa TSUTSUMI ; Koji SAWADA ; Tatsuji MAESHIRO ; Hiroshi TOBITA ; Yuichi YOSHIDA ; Masafumi NAITO ; Asuka ARAKI ; Shingo ARAKAKI ; Takumi KAWAGUCHI ; Hidenao NORITAKE ; Masafumi ONO ; Tsutomu MASAKI ; Satoshi YASUDA ; Eiichi TOMITA ; Masato YONEDA ; Akihiro TOKUSHIGE ; Yoshihiro KAMADA ; Hirokazu TAKAHASHI ; Shinichiro UEDA ; Shinichi AISHIMA ; Yoshio SUMIDA ; Atsushi NAKAJIMA ; Takeshi OKANOUE ;
Clinical and Molecular Hepatology 2024;30(2):225-234
Background/Aims:
Metabolic dysfunction-associated steatotic liver disease (MASLD) was recently proposed as an alternative disease concept to nonalcoholic fatty liver disease (NAFLD). We aimed to investigate the prognosis of patients with biopsy-confirmed MASLD using data from a multicenter study.
Methods:
This was a sub-analysis of the Clinical Outcome Nonalcoholic Fatty Liver Disease (CLIONE) study that included 1,398 patients with NAFLD. Liver biopsy specimens were pathologically diagnosed and histologically scored using the NASH Clinical Research Network system, the FLIP algorithm, and the SAF score. Patients who met at least one cardiometabolic criterion were diagnosed with MASLD.
Results:
Approximately 99% of cases (n=1,381) were classified as MASLD. Patients with no cardiometabolic risk (n=17) had a significantly lower BMI than patients with MASLD (20.9 kg/m2 vs. 28.0 kg/m2, P<0.001), in addition to significantly lower levels of inflammation, ballooning, NAFLD activity score, and fibrosis stage based on liver histology. These 17 patients had a median follow-up of 5.9 years, equivalent to 115 person-years, with no deaths, liver-related events, cardiovascular events, or extrahepatic cancers. The results showed that the prognosis for pure MASLD was similar to that for the original CLIONE cohort, with 47 deaths and one patient who underwent orthotopic liver transplantation. The leading cause of death was extrahepatic cancer (n=10), while the leading causes of liver-related death were liver failure (n=9), hepatocellular carcinoma (n=8), and cholangiocarcinoma (n=4).
Conclusions
Approximately 99% of NAFLD cases were considered MASLD based on the 2023 liver disease nomenclature. The NAFLD-only group, which is not encompassed by MASLD, had a relatively mild histopathologic severity and a favorable prognosis. Consequently, the prognosis of MASLD is similar to that previously reported for NAFLD.